HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Are EGFR mutations primarily a concern among Asian populations? Ming-Sound Tsao, MD; Tony S. K. Mok, MD
-
- EGFR biomarkers turn NSCLC decision-making in a new direction
- Although trials in elderly increasing, better data still needed
- GeparQuattro: Neoadjuvant trastuzumab improved response rate for HER-2–positive breast cancer
- Health care reform, consultation codes and off-label drug use all big issues for hem/oncs Samuel M. Silver, MD, PhD
- Newer surgical, treatment methods look promising for gynecologic cancers
- The role of initial maximal surgical cytoreduction in ovarian cancer still debated Maurie Markman, MD
- Finding a way to help: Cutting edge research and modern medicine are not always enough William Wood, MD
- Adult survivors of childhood cancer have decreased life expectancy
-
- Contralateral breast cancer higher among those with ATM gene mutations treated with radiation
- High-dose cyclophosphamide effective treatment for severe aplastic anemia
- Outcomes similar between blacks, whites treated at specialized cancer centers
- Follow-up sonography without surgery viable for patients with ovarian cysts
- Simplified GOG risk criteria validated in stage IB cervical cancers
- ABHR gel for refractory nausea and vomiting Lisa K. Lohr, PharmD, BCPS, BCOP